Researchers at Mayo Clinic presented data at DDW 2026 demonstrating that the TissueCypher molecular test enhances risk stratification for Barrett's esophagus patients. The test better predicts progression to serious conditions like high-grade dysplasia or esophageal cancer compared to traditional methods, leading to changes in surveillance intervals for over half of patients. This allows for more personalized, risk-aligned management, potentially improving outcomes by escalating care for higher-risk patients and reducing unnecessary procedures for lower-risk individuals. The findings support integrating TissueCypher into clinical practice to guide more effective patient monitoring and treatment decisions.
Autonomize, a healthcare AI platform, has strengthened its leadership by appointing three industry veterans to its Advisory Board and hiring Mike Longacre as Head of Transformation. These moves aim to help healthcare organizations move beyond AI pilo...
Fairfax Financial Holdings has finalized its acquisition of Kennedy-Wilson Holdings at $10.90 per share in cash, led by a consortium including Kennedy Wilson's CEO William McMorrow and affiliates of Fairfax. The Kennedy Wilson management team retains...
Aya Gold & Silver Inc., a Canadian precious metals mining company operating in Morocco, will be added to the VanEck Gold Miners ETF (GDX) effective June 19, 2026. This inclusion marks a significant milestone reflecting the company's growth in product...
Nephros, Inc. emphasizes its ultrafiltration technology's ability to capture microplastics and nanoplastics in water, following the U.S. EPA's April 2026 decision to list microplastics as a priority contaminant under the Safe Drinking Water Act. The ...
After the US and Iran reached a deal expected to reopen the Strait of Hormuz, the world's largest tanker owner, Mitsui OSK Lines, cautions that shipping companies will wait for proof the agreement works before resuming normal traffic. The strait is c...
